GB2626503A - Treatment methods for ALS patients - Google Patents
Treatment methods for ALS patients Download PDFInfo
- Publication number
- GB2626503A GB2626503A GB2406210.1A GB202406210A GB2626503A GB 2626503 A GB2626503 A GB 2626503A GB 202406210 A GB202406210 A GB 202406210A GB 2626503 A GB2626503 A GB 2626503A
- Authority
- GB
- United Kingdom
- Prior art keywords
- subject
- chlorite
- als
- crp
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract 153
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title claims 112
- 229910001919 chlorite Inorganic materials 0.000 claims 84
- 229910052619 chlorite group Inorganic materials 0.000 claims 84
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 claims 84
- 108010074051 C-Reactive Protein Proteins 0.000 claims 80
- 102100032752 C-reactive protein Human genes 0.000 claims 78
- 208000024891 symptom Diseases 0.000 claims 57
- 239000000203 mixture Substances 0.000 claims 23
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 claims 21
- 229960002218 sodium chlorite Drugs 0.000 claims 21
- 206010013975 Dyspnoeas Diseases 0.000 claims 20
- 239000004816 latex Substances 0.000 claims 18
- 229920000126 latex Polymers 0.000 claims 18
- 206010009696 Clumsiness Diseases 0.000 claims 10
- 206010013887 Dysarthria Diseases 0.000 claims 10
- 208000000059 Dyspnea Diseases 0.000 claims 10
- 208000007101 Muscle Cramp Diseases 0.000 claims 10
- 208000010428 Muscle Weakness Diseases 0.000 claims 10
- 206010028347 Muscle twitching Diseases 0.000 claims 10
- 206010028372 Muscular weakness Diseases 0.000 claims 10
- 206010039424 Salivary hypersecretion Diseases 0.000 claims 10
- 206010071299 Slow speech Diseases 0.000 claims 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 10
- 208000005392 Spasm Diseases 0.000 claims 10
- 230000001055 chewing effect Effects 0.000 claims 10
- 230000009194 climbing Effects 0.000 claims 10
- 210000003205 muscle Anatomy 0.000 claims 10
- 208000013220 shortness of breath Diseases 0.000 claims 10
- 208000026473 slurred speech Diseases 0.000 claims 10
- 230000009747 swallowing Effects 0.000 claims 10
- 230000004520 agglutination Effects 0.000 claims 9
- 238000003018 immunoassay Methods 0.000 claims 9
- 238000004848 nephelometry Methods 0.000 claims 9
- 239000002245 particle Substances 0.000 claims 9
- 238000005375 photometry Methods 0.000 claims 9
- 230000037396 body weight Effects 0.000 claims 8
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 claims 6
- 238000003745 diagnosis Methods 0.000 claims 6
- -1 hnRNPA2Bl Proteins 0.000 claims 6
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- 101000891092 Homo sapiens TAR DNA-binding protein 43 Proteins 0.000 claims 4
- 210000000349 chromosome Anatomy 0.000 claims 4
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 238000003556 assay Methods 0.000 claims 3
- 230000007170 pathology Effects 0.000 claims 3
- 102100022987 Angiogenin Human genes 0.000 claims 2
- 102100028118 Annexin A11 Human genes 0.000 claims 2
- 102000007370 Ataxin2 Human genes 0.000 claims 2
- 108010032951 Ataxin2 Proteins 0.000 claims 2
- 108700030955 C9orf72 Proteins 0.000 claims 2
- 101150014718 C9orf72 gene Proteins 0.000 claims 2
- 101150108055 CHMP2B gene Proteins 0.000 claims 2
- 102100038700 Calcium-responsive transactivator Human genes 0.000 claims 2
- 102100038279 Charged multivesicular body protein 2b Human genes 0.000 claims 2
- 102100023677 Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrial Human genes 0.000 claims 2
- 101710137943 Complement control protein C3 Proteins 0.000 claims 2
- 102100036654 Dynactin subunit 1 Human genes 0.000 claims 2
- 102100035074 Elongator complex protein 3 Human genes 0.000 claims 2
- 102100029301 Guanine nucleotide exchange factor C9orf72 Human genes 0.000 claims 2
- 102100035621 Heterogeneous nuclear ribonucleoprotein A1 Human genes 0.000 claims 2
- 101000757236 Homo sapiens Angiogenin Proteins 0.000 claims 2
- 101000768066 Homo sapiens Annexin A11 Proteins 0.000 claims 2
- 101000957728 Homo sapiens Calcium-responsive transactivator Proteins 0.000 claims 2
- 101000907013 Homo sapiens Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrial Proteins 0.000 claims 2
- 101000929626 Homo sapiens Dynactin subunit 1 Proteins 0.000 claims 2
- 101000877382 Homo sapiens Elongator complex protein 3 Proteins 0.000 claims 2
- 101000854014 Homo sapiens Heterogeneous nuclear ribonucleoprotein A1 Proteins 0.000 claims 2
- 101000957559 Homo sapiens Matrin-3 Proteins 0.000 claims 2
- 101001111338 Homo sapiens Neurofilament heavy polypeptide Proteins 0.000 claims 2
- 101000992283 Homo sapiens Optineurin Proteins 0.000 claims 2
- 101001129178 Homo sapiens Patatin-like phospholipase domain-containing protein 6 Proteins 0.000 claims 2
- 101000987578 Homo sapiens Peripherin Proteins 0.000 claims 2
- 101000827703 Homo sapiens Polyphosphoinositide phosphatase Proteins 0.000 claims 2
- 101000836337 Homo sapiens Probable helicase senataxin Proteins 0.000 claims 2
- 101000577619 Homo sapiens Profilin-1 Proteins 0.000 claims 2
- 101000644537 Homo sapiens Sequestosome-1 Proteins 0.000 claims 2
- 101001123846 Homo sapiens Serine/threonine-protein kinase Nek1 Proteins 0.000 claims 2
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 claims 2
- 101000836994 Homo sapiens Sigma non-opioid intracellular receptor 1 Proteins 0.000 claims 2
- 101001099181 Homo sapiens TATA-binding protein-associated factor 2N Proteins 0.000 claims 2
- 101000788548 Homo sapiens Tubulin alpha-4A chain Proteins 0.000 claims 2
- 101000607639 Homo sapiens Ubiquilin-2 Proteins 0.000 claims 2
- 101000775932 Homo sapiens Vesicle-associated membrane protein-associated protein B/C Proteins 0.000 claims 2
- 102100038645 Matrin-3 Human genes 0.000 claims 2
- 102100024007 Neurofilament heavy polypeptide Human genes 0.000 claims 2
- 102100031822 Optineurin Human genes 0.000 claims 2
- 102100031254 Patatin-like phospholipase domain-containing protein 6 Human genes 0.000 claims 2
- 102100028465 Peripherin Human genes 0.000 claims 2
- 102100023591 Polyphosphoinositide phosphatase Human genes 0.000 claims 2
- 102100027178 Probable helicase senataxin Human genes 0.000 claims 2
- 102100028857 Profilin-1 Human genes 0.000 claims 2
- 108090000740 RNA-binding protein EWS Proteins 0.000 claims 2
- 102000004229 RNA-binding protein EWS Human genes 0.000 claims 2
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims 2
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims 2
- 102100020814 Sequestosome-1 Human genes 0.000 claims 2
- 102100028751 Serine/threonine-protein kinase Nek1 Human genes 0.000 claims 2
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 claims 2
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 claims 2
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 claims 2
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 claims 2
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 claims 2
- 102100038917 TATA-binding protein-associated factor 2N Human genes 0.000 claims 2
- 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 claims 2
- 101710132062 Transitional endoplasmic reticulum ATPase Proteins 0.000 claims 2
- 102100025239 Tubulin alpha-4A chain Human genes 0.000 claims 2
- 102100039933 Ubiquilin-2 Human genes 0.000 claims 2
- 102100032026 Vesicle-associated membrane protein-associated protein B/C Human genes 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 208000013967 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 Diseases 0.000 claims 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims 2
- 238000001964 muscle biopsy Methods 0.000 claims 2
- 230000007830 nerve conduction Effects 0.000 claims 2
- ODLMAHJVESYWTB-UHFFFAOYSA-N propylbenzene Chemical compound CCCC1=CC=CC=C1 ODLMAHJVESYWTB-UHFFFAOYSA-N 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 206010061818 Disease progression Diseases 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- VISKNDGJUCDNMS-UHFFFAOYSA-M potassium;chlorite Chemical compound [K+].[O-]Cl=O VISKNDGJUCDNMS-UHFFFAOYSA-M 0.000 claims 1
- 230000009325 pulmonary function Effects 0.000 claims 1
- 229920001621 AMOLED Polymers 0.000 abstract 4
- 239000006096 absorbing agent Substances 0.000 abstract 1
- 230000003667 anti-reflective effect Effects 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 238000004544 sputter deposition Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252061P | 2021-10-04 | 2021-10-04 | |
| US202263301476P | 2022-01-20 | 2022-01-20 | |
| US202263302000P | 2022-01-21 | 2022-01-21 | |
| PCT/US2022/077557 WO2023060097A1 (en) | 2021-10-04 | 2022-10-04 | Treatment methods for als patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB202406210D0 GB202406210D0 (en) | 2024-06-19 |
| GB2626503A true GB2626503A (en) | 2024-07-24 |
Family
ID=85804736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2406210.1A Pending GB2626503A (en) | 2021-10-04 | 2022-10-04 | Treatment methods for ALS patients |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12329776B2 (https=) |
| EP (1) | EP4412624A4 (https=) |
| JP (1) | JP2024533873A (https=) |
| AU (1) | AU2022360976A1 (https=) |
| CA (1) | CA3233863A1 (https=) |
| GB (1) | GB2626503A (https=) |
| WO (1) | WO2023060097A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017079161A2 (en) | 2015-11-02 | 2017-05-11 | Neuraltus Pharmaceuticals, Inc. | Treatment of neurodegenerative disease with sodium chlorite |
| EP4412624A4 (en) | 2021-10-04 | 2025-08-20 | Neuvivo Inc | TREATMENT METHODS FOR ALS PATIENTS |
| GB2637227A (en) | 2022-05-19 | 2025-07-16 | Neuvivo Inc | Biomarkers for neurogenerative disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014057880A1 (ja) * | 2012-10-12 | 2014-04-17 | 藤倉化成株式会社 | Ｃ－反応性タンパク質測定用の測定試薬および測定方法 |
| WO2015175974A1 (en) * | 2014-05-16 | 2015-11-19 | Neuraltus Pharmaceuticals, Inc. | Methods and compositions for treatment of macrophage-related disorders |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011205095B2 (en) * | 2004-02-03 | 2014-07-03 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| US7105183B2 (en) | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| US20060051790A1 (en) | 2004-07-01 | 2006-03-09 | The Regents Of The University Of California | Genetic risk factor for neurodegenerative disease |
| JP5421590B2 (ja) | 2005-05-18 | 2014-02-19 | ノバルティス アーゲー | 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法 |
| JP5371443B2 (ja) | 2005-12-22 | 2013-12-18 | ニューラルタス ファーマシューティカルズ，インコーポレイテッド | 亜塩素酸塩製剤、およびこの調製の方法と利用 |
| WO2008042190A2 (en) | 2006-09-29 | 2008-04-10 | The Trustees Of The University Of Pennsylvania | Detection of neurodegenerative disease |
| BR112012002333A2 (pt) | 2009-08-06 | 2017-07-18 | Neuraltus Pharmaceuticals Inc | método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito. |
| US8465727B2 (en) | 2009-10-06 | 2013-06-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Biomarkers for the diagnosis of ALS |
| US20140147856A1 (en) | 2012-11-29 | 2014-05-29 | Rush University Medical Center | Intestinal Permeability Assay for Neurodegenerative Diseases |
| RU2653754C2 (ru) | 2012-12-06 | 2018-05-14 | Пин Фарма, Инк. | Лечение воспалительных, аутоиммунных и нейродегенеративных нарушений иммуннодепрессивными полипетидами, являющимися производными тат |
| CA3112130A1 (en) | 2013-07-11 | 2015-01-15 | University Of North Texas Health Science Center At Fort Worth | Blood-based screen for detecting neurological diseases in primary care settings |
| EP3116481A1 (en) * | 2014-03-13 | 2017-01-18 | Vasilios VOUDOURIS | Bendamustine solid dispersions and continuous infusion |
| WO2017079161A2 (en) | 2015-11-02 | 2017-05-11 | Neuraltus Pharmaceuticals, Inc. | Treatment of neurodegenerative disease with sodium chlorite |
| US20190060359A1 (en) | 2015-11-02 | 2019-02-28 | Neuraltus Pharmaceuticals, Inc. | Treatment of neurodegenerative disease with sodium chlorite |
| AU2022277010A1 (en) | 2021-05-18 | 2023-12-14 | Rijksuniversiteit Groningen | Nanopore proteomics |
| EP4412624A4 (en) | 2021-10-04 | 2025-08-20 | Neuvivo Inc | TREATMENT METHODS FOR ALS PATIENTS |
| JP2025518096A (ja) | 2022-05-27 | 2025-06-12 | エレドン ファーマシューティカルズ，インコーポレイテッド | 筋萎縮性側索硬化症の治療方法 |
-
2022
- 2022-10-04 EP EP22879435.0A patent/EP4412624A4/en active Pending
- 2022-10-04 JP JP2024544620A patent/JP2024533873A/ja active Pending
- 2022-10-04 AU AU2022360976A patent/AU2022360976A1/en active Pending
- 2022-10-04 WO PCT/US2022/077557 patent/WO2023060097A1/en not_active Ceased
- 2022-10-04 CA CA3233863A patent/CA3233863A1/en active Pending
- 2022-10-04 GB GB2406210.1A patent/GB2626503A/en active Pending
-
2023
- 2023-02-10 US US18/167,245 patent/US12329776B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014057880A1 (ja) * | 2012-10-12 | 2014-04-17 | 藤倉化成株式会社 | Ｃ－反応性タンパク質測定用の測定試薬および測定方法 |
| WO2015175974A1 (en) * | 2014-05-16 | 2015-11-19 | Neuraltus Pharmaceuticals, Inc. | Methods and compositions for treatment of macrophage-related disorders |
Non-Patent Citations (4)
| Title |
|---|
| Anonymous, "In ALS, Respiratory Measure Predicts Pace of Disease" pgs 1-5, In ALS, Respiratory Masure Predicts Pace of Disease, ALZFORUM, Webpage, 01 December 2017, pg 1, first bullet point * |
| Joyce N C et al., "Electrodiagnosis in Persons With Amyotrophic Lateral Sclerosis", pgs 1-15, PM&R., Web, May 2013, Abstract, pg 4, paragraph 3, doi:10.1016/j.pmrj.2013.03.020 * |
| Simeonovska-Joveva E et al., "Differential diagnosis between Bulbospinal muscular atrophy - Kennedy's disease and Amyotrophic lateral sclerosis", pgs 77-81, Acta Medica Medianae 2019, Vol. 58(2), Web, 2019, Abstract, doi:10.5633/amm.2019.0213 * |
| Walker K et al., "The association of mid-to late-life systemic inflammation with white matter structure in older adults: The ARIC Study", 1-18, Neurobiol Aging, 2018 August, Vol. 68, pgs 26-33, Web, August 2018, pg 3, last paragraph, doi:10.1016/j.neurobiolaging.2018.03.031 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024533873A (ja) | 2024-09-12 |
| EP4412624A1 (en) | 2024-08-14 |
| CA3233863A1 (en) | 2023-04-13 |
| WO2023060097A1 (en) | 2023-04-13 |
| EP4412624A4 (en) | 2025-08-20 |
| AU2022360976A1 (en) | 2024-05-02 |
| GB202406210D0 (en) | 2024-06-19 |
| US20230190790A1 (en) | 2023-06-22 |
| US12329776B2 (en) | 2025-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2626503A (en) | Treatment methods for ALS patients | |
| Ferastraoaru et al. | Eosinophilia in asthma patients is protective against severe COVID-19 illness | |
| Hunninghake et al. | Sensitization to Ascaris lumbricoides and severity of childhood asthma in Costa Rica | |
| Fragoso et al. | Frailty and respiratory impairment in older persons | |
| Murphy et al. | Characterization of macrophage activation states in patients with cystic fibrosis | |
| Kuo et al. | Association of cardiorespiratory fitness and levels of C-reactive protein: data from the National Health and Nutrition Examination Survey 1999–2002 | |
| Woodcock et al. | Genetic, radiologic, and clinical variability in Brown-Vialetto-van Laere syndrome | |
| Kim et al. | Impact of body mass index change on the prognosis of chronic obstructive pulmonary disease | |
| Mahai et al. | Exposure to multiple neonicotinoid insecticides, oxidative stress, and gestational diabetes mellitus: association and potential mediation analyses | |
| Bendien et al. | Bronchiectasis in severe asthma: does it make a difference? | |
| JP2024533873A5 (https=) | ||
| Lin et al. | Initial national institute of health stroke scale to early predict the improvement of swallowing in patients with acute ischemic stroke | |
| CN111602057A (zh) | 使用降钙素原和中区肾上腺髓质素原的风险评估和患者管理的工作流程 | |
| Maniscalco et al. | Association between exhaled nitric oxide and nasal polyposis in severe asthma | |
| Wark et al. | Safety of sputum induction with isotonic saline in adults with acute severe asthma | |
| Chawes | Low-grade disease activity in early life precedes childhood asthma and allergy | |
| JP2011256145A (ja) | Ｔｈ３マーチ関連疾患の治療及び予防用医薬組成物 | |
| Peng et al. | Motor function and compound muscle action potential amplitude in children with spinal muscular atrophy treated with nusinersen | |
| HK40115296A (en) | Treatment methods for als patients | |
| Makris et al. | Dyspnea assessment and adverse events during sputum induction in COPD | |
| Ireson et al. | Comparison of nasal pH values in black and white individuals with normal and high blood pressure | |
| Yang et al. | Low serum indium levels induce expression disorders of some inflammatory factors | |
| Jang | Nasal eosinophilic inflammation contributes to bronchial hyperresponsiveness in patients with allergic rhinitis | |
| Campos-Rodriguez et al. | Continuous positive airway pressure treatment does not reduce uric acid levels in OSA women | |
| Sahni et al. | Correlation between vitamin D deficiency and benign paroxysmal positional vertigo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40115296 Country of ref document: HK |